Key result
Senolytics and senomorphics show therapeutic potential for HFpEF despite tissue specificity and biomarker barriers.
Why the study?
Heart failure with preserved ejection fraction is strongly associated with aging, and cellular senescence with the senescence-associated secretory phenotype significantly contributes to its pathogenesis and progression.
Targeting cellular senescence and SASP pathways represents a promising but early-stage therapeutic strategy for addressing the underlying pathophysiology of HFpEF.
SASP targeting in HFpEF remains hypothesis-generating; prospective trials needed before any clinical adoption.
Heart failure with preserved ejection fraction (HFpEF) represents a complex syndrome strongly associated with aging, characterized by diastolic dysfunction, myocardial stiffness, and chronic low-grade inflammation. Cellular senescence and the ensuing senescence-associated secretory phenotype (SASP) significantly contribute to the pathogenesis and progression of HFpEF. This review examines the biological properties of SASP and its mechanistic roles in driving myocardial fibrosis, microvascular dysfunction, and cardiomyocyte injury. We synthesize evidence from preclinical and clinical studies demonstrating how SASP factors orchestrate HFpEF pathophysiology. The therapeutic potential of targeting SASP pathways is critically evaluated, including senolytic agents that eliminate senescent cells and senomorphic compounds that inhibit SASP factor secretion. Finally, we identify key translational barriers, such as limited tissue specificity in senolytic delivery and inadequate SASP biomarkers for treatment monitoring, while outlining future research directions to advance novel therapeutic development for this increasingly prevalent condition.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Senolytic agents and senomorphic compounds was evaluated. Targeting cellular senescence and the SASP with senolytics and senomorphics offers therapeutic potential for HFpEF, though limited tissue specificity and inadequate biomarkers remain key barriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: